2023 World Conference on Lung Cancer (Posters)-P1.25. Prognostic Impact of Exon20 Insertion in Surgically Resected Lung Adenocarcinoma Harboring Atypical EGFR Single Mutation

P1.25. Prognostic Impact of Exon20 Insertion in Surgically Resected Lung Adenocarcinoma Harboring Atypical EGFR Single Mutation - PDF(Abstract)

Back to course

Pdf Summary

This study aimed to investigate the prognostic impact of EGFR (Epidermal Growth Factor Receptor) exon20 insertion mutation in patients with surgically resected lung adenocarcinoma. The researchers compared the survival outcomes of patients with exon20 insertion mutation to those harboring major atypical mutation.<br /><br />A total of 843 patients who underwent surgical resection for lung adenocarcinoma and were confirmed to have EGFR atypical single mutation were included in the study. Among them, 340 patients had exon20 insertion mutation and 503 patients had major atypical mutation. The researchers compared disease-free survival (DFS) between the two groups and also evaluated whether these patients could benefit from adjuvant chemotherapy for DFS. Additionally, overall survival (OS) and post-recurrence survival (PRS) were compared to investigate the recurrence pattern.<br /><br />The results showed that patients with exon20 insertion mutation had marginally favorable DFS compared to those with major atypical mutation. Multivariable analysis revealed that EGFR exon20 insertion mutation was an independent predictor for favorable DFS. However, both patients with exon20 insertion mutation and those with major atypical mutation did not benefit from adjuvant chemotherapy for DFS. Among the patients who experienced recurrence, those with exon20 insertion mutation had significantly worse PRS compared to those with major atypical mutation. Multivariable analysis demonstrated that exon20 insertion mutation was an independent predictor for worse OS and worse PRS.<br /><br />In conclusion, patients with EGFR exon20 insertion mutation had favorable DFS but worse OS and PRS compared to those with major atypical mutation in surgically resected lung adenocarcinoma. Neither exon20 insertion mutation nor major atypical mutation could benefit from adjuvant chemotherapy.

Asset Subtitle

Tao Chen

Meta Tag

Speaker Tao Chen

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

EGFR exon20 insertion mutation

prognostic impact

lung adenocarcinoma

surgical resection

survival outcomes

atypical mutation

disease-free survival

adjuvant chemotherapy

overall survival

post-recurrence survival